Top View
- Is Edoxaban for My Patient? (From CLOT Group)
- Clinical Evidence of the Role of Edoxaban in Anticoagulation
- View Wanese Patients Following TKA [5], THA [6], and Hip Frac- Boards at Each Study Center, and Written Informed Consent Ture Surgery [7]
- Study Protocol
- Management of Bleeding in Patients Treated with Direct Oral Anticoagulants Marcel Levi1,2
- Prior Authorization Anticoagulants – Savaysa® (Edoxaban Tablets)
- Endoscopy in Patients on Antiplatelet Or Anticoagulant Therapy, Including Direct Oral Anticoagulants
- Inclusions and Exclusions for IV
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- Edoxaban (Savaysa): What You Need to Know and Do
- Practice Guide to Dosing of Direct Acting Oral
- Edoxaban (Savaysa®)
- Treatment of Pregnancy-Associated Venous Thromboembolism – Position Paper from the Working Group in Women’S Health of the Society of Thrombosis and Haemostasis (GTH)
- (Doacs) APIXABAN/DABIGATRAN/EDOXABAN/RIVAROXABAN
- SAVAYSA (Edoxaban) Tablets for Oral Use Ml/Min (2.1) Initial U.S
- Guidance on Safe Switching of Warfarin to DOAC
- Quantification of Apixaban in Human Plasma Using Ultra Performance Liquid Chromatography Coupled with Tandem Mass Spectrometry
- Bericht ATC-Code B01: Antithrombotische Mittel
- CPG.41 Prescribing of Direct Oral Anticoagulants (Doacs)
- Anticoagulants and Osteoporosis
- Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early
- Edoxaban (Lixiana®)
- Direct Oral Anticoagulants: from Randomized Clinical Trials to Real-World Clinical Practice
- Edoxaban Patient Information Sheet Also Known As: Lixiana®
- Antiplatelets and Anticoagulation in Stroke – Quick Reference Guide Clinical Guideline
- Which Direct Oral Anticoagulant (DOAC) Is Best for My Patient?
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Management of Dental Patients Taking Anticoagulants Or Antiplatelets
- Oral Direct Thrombin Inhibitors Or Oral Factor Xa Inhibitors for the Treatment of Pulmonary Embolism (Review)
- Edoxaban (Savaysa®)
- Acute Coronary Syndrome [G] Combination Therapy
- Direct-Acting Oral Anticoagulant Use at Extremes of Body Weight
- Dabigatran, Rivaroxaban, Edoxaban and Apixaban for AF
- Cdr Clinical Review Report for Lixiana
- Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
- Switching to and from Various Anticoagulants
- Measuring Concentrations of Rivaroxaban, Apixaban, Edoxaban
- Anticoagulant and Antiplatelet Medication GL067
- Direct Oral Anticoagulants (Doacs) Guide
- Enoxaparin – Prescribing, Administration and Monitoring
- Edoxaban (Savaysa®) What You Need to Know
- Ag-Atc-Beschluss-20151127.Pdf
- Unanswered Questions During the Live Event
- Edoxaban (SAVAYSA) National Drug Monograph October 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- Edoxaban Improves Venous Thrombosis Via Increasing Hydrogen Sulfide and Homocysteine in Rat Model
- Efficacy and Safety of Edoxaban Versus Enoxaparin
- Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: a Systematic Review of the Literature and Analysis of Vigibase
- BIOPHEN™ Dixai Edoxaban) : Low Range Standard Range Sysmex CS-5100 : N = 142 Y = 1.00X + 13.10 R = 0.997 Refer to the Specific Application Guide for Each Analyzer
- Conversions (“Switching”) Among the Oral Anticoagulants
- Patients' Serum and Urine As Easily Accessible Samples for the Measurement of Non–Vitamin K Antagonist Oral Anticoagulants
- Medicines for Stroke Prevention in Atrial Fibrillation Choosing the Right One for You
- Clinical Trial Protocol Doc